Shanghai Hegno

Hegno is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative protein degradation therapies. The company leverages its proprietary PROTAC (Proteolysis-Targeting Chimera) technology platform to target previously undruggable proteins involved in cancer and other serious diseases. Hegno's pipeline is primarily focused on oncology, with lead programs targeting the androgen receptor for prostate cancer and the estrogen receptor for breast cancer. By utilizing the body's natural protein disposal system, Hegno aims to provide more effective and durable treatment options for patients with resistant or refractory tumors.